Ozurdex (dexamethasone intravitreal implant) / AbbVie - LARVOL DELTA

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema. (PubMed, Am J Ophthalmol Case Rep) - "This manuscript describes a case of recalcitrant postoperative cystoid macular edema (CME), confounded by a history of branch retinal vein occlusion (BRVO), in which faricimab resulted in resolution of CME after incomplete response to topical anti-inflammation drops, intravitreal aflibercept and bevacizumab, a corticosteroid intravitreal implant, grid laser therapy, and suprachoroidal triamcinolone acetonide (SCS-TA)...CME persisted for eight years despite treatment with topical anti-inflammatories, anti-VEGF injections, a dexamethasone intravitreal implant, grid laser therapy, and a SCS-TA injection...This case demonstrates the effectiveness of faricimab in treatment of CME resistant to other therapies and the importance of continued attempts at using new agents for chronic, recurrent CME. The unique benefits of new agents like faricimab, with both VEGF and Ang-2 inhibition, may be particularly helpful in mixed or inflammatory CME when other proven therapies have failed."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Glaucoma • Inflammation • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Presumed Ocular Tuberculosis: Insights from an Egyptian Cohort. (PubMed, Ocul Immunol Inflamm) - "Periocular corticosteroids were required in 14 patients (33.3%) and intravitreal Ozurdex injections in 6 patients (14.3%) to control intraocular inflammation and cystoid macular edema...In our cohort, anterior and intermediate uveitis were the most common presentations. Most cases were treated with antituberculous treatment whether alone or combined with oral corticosteroids for optimal disease control."

Journal • Cardiovascular • Cataract • Glaucoma • Infectious Disease • Inflammation • Macular Edema • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Scleritis • Tuberculosis • Uveitis

Real-life short-term experience of switching from other anti-VEGF therapy to faricimab in patients with refractory macular edema secondary to retinal vein occlusion in China. (PubMed, Int Ophthalmol) - "This study demonstrates that faricimab significantly improves visual acuity and reduces CMT in previously treated RVO-ME patients, with a favorable safety profile."

Journal • Retrospective data • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Safety and efficacy of ranibizumab combined with dexamethasone intravitreal implant versus ranibizumab monotherapy for macular edema secondary to retinal vein occlusion: a 12-month prospective, randomized study. (PubMed, Int Ophthalmol) - "Combination therapy with ranibizumab and a dexamethasone implant provides superior visual outcomes and reduces the treatment burden compared to ranibizumab monotherapy for RVO-ME over 12 months. The safety profile was favorable, though monitoring for ocular hypertension is necessary. These benefits are particularly significant for patients with BRVO-ME."

Clinical • Journal • Monotherapy • Cardiovascular • Glaucoma • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Long-term follow-up and treatment of lamellar hole-associated epiretinal proliferation presenting with exudative perivascular anomalous complex. (PubMed, Am J Ophthalmol Case Rep) - "The intraocular pressure was between normal limits during the follow-up period. Anti-VEGF therapy is less effective than dexamethasone intravitreal implant with a treatment interval greater than 12 weeks."

Journal • Cardiovascular • Cataract • Diabetes • Hematological Disorders • Hypertension • Metabolic Disorders • Ophthalmology • Retinal Disorders

Bilateral idiopathic macular telangiectasia type 1 in an elderly female: A case report. (PubMed, Medicine (Baltimore)) - "This case of bilateral MacTel 1 in a female provides valuable insights into multimodal imaging studies and interventions for this uncommon condition."

Journal • Cardiovascular • Hypertension • Macular Edema • Ophthalmology

Topical Prednisolone Acetate Challenge as a Predictor of Intraocular Pressure Elevation Following Ozurdex® in Diabetic Macular Edema: A Retrospective Study. (PubMed, Cureus) - "Conclusion A short-term topical prednisolone acetate challenge provides moderate predictive value for identifying eyes at risk of IOP elevation following Ozurdex implantation. While not a perfect predictor, this inexpensive and non-invasive test may assist clinicians in tailoring post-injection monitoring strategies, particularly in resource-limited or high-volume care settings."

Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Glaucoma • Ophthalmology

Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: John L. Reagan | Active, not recruiting ➔ Completed

Trial completion • Hematological Malignancies • Multiple Myeloma • Oncology

COHOST: Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: University of Nebraska | Trial primary completion date: Jan 2027 ➔ Jul 2027

Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

A Case of Anterior Vitreous Displacement of the Intravitreal Dexamethasone Implant (Ozurdex®) in a Pseudophakic Eye. (PubMed, Cureus) - "A conservative "watch-and-wait" approach with close monitoring is sufficient. Our case emphasizes preventive strategies, including identifying at-risk patients, using a careful injection technique, and performing meticulous slit-lamp evaluation in cases of migration."

Journal • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty (clinicaltrials.gov) - P4 | N=244 | Completed | Sponsor: Hospital for Special Surgery, New York | Recruiting ➔ Completed | Trial completion date: May 2026 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Sep 2025

Trial completion • Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain

Outcome of silicone oil tamponade combined dexamethasone implantation in patients with proliferative diabetic retinopathy and retinal detachment undergoing vitrectomy: a prospective randomized controlled clinical trial. (PubMed, BMC Ophthalmol) - "In patients with proliferative diabetes retinopathy complicated with retinal detachment, the combination of vitrectomy with silicone oil tamponade and dexamethasone implantation can reduce the incidence of preretinal proliferative membrane and macular epiretinal membrane and improve the visual outcome during 1 year follow-up."

Clinical • Journal • Diabetes • Diabetic Retinopathy • Metabolic Disorders • Retinal Disorders

The relationship between the intraocular position of dexamethasone intravitreal implant and post-injection intraocular pressure elevation. (PubMed, Front Med (Lausanne)) - "Compared to P2 and P3, the P1 implantation position was significantly associated with a higher incidence of IOP elevation (p < 0.001) and was positively correlated with early IOP elevation (within 15 days post-injection) (r = 0.761; p < 0.001). The P1 implantation is positively correlated with IOP elevation, particularly with early IOP elevation."

Journal

A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China (clinicaltrials.gov) - P=N/A | N=110 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Diabetic Macular Edema • Ophthalmology

The Role of Adding Intravitreal Dexamethasone Implant to the Standard Management of Serpiginous Choroiditis for Achieving Rapid Remission: A Case Report. (PubMed, Int Med Case Rep J) - "To prevent systemic adverse effects and obtain rapid control of serpiginous lesions, as necessary in the case presented, local therapy using a dexamethasone intravitreal implant may be considered as a complement to systemic treatment...The patient was started oral prednisolone 0.5 mg/kg tapering; however, because the patient would be traveling for three weeks, the systemic oral steroid with an intravitreal dexamethasone implant in each eye...After starting Azathioprine, disease activity was suppressed for six months without relapsing. This case raises a question about the benefit of combined therapy for quick vision restoration, inhibiting further destruction of outer retinal layers during the management of acute attack and reduction of overall systemic steroids dose together with its complications versus the risk of local steroids administration and cost-effectiveness. Additional research is required to validate this finding."

Journal • Infectious Disease • Ocular Inflammation • Ophthalmology • Uveitis

STAMP: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (clinicaltrials.gov) - P4 | N=16 | Completed | Sponsor: Bay Area Retina Associates | Recruiting ➔ Completed | N=32 ➔ 16

Enrollment change • Trial completion • Cataract • Diabetic Macular Edema • Ophthalmology

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=28 | Active, not recruiting | Sponsor: University of Rochester | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

OXEYE: Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=3 | Completed | Sponsor: Oxular Limited | Active, not recruiting ➔ Completed

Trial completion • Diabetic Macular Edema • Ophthalmology

Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty (clinicaltrials.gov) - P4 | N=244 | Recruiting | Sponsor: Hospital for Special Surgery, New York | Trial primary completion date: May 2025 ➔ Dec 2025

Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain

Clinical research of portable detective technology fo aqeous humor on retianl vein occlusion secondary to macular edema (ChiCTR) - P=N/A | N=56 | Not yet recruiting | Sponsor: Shenzhen Eye Hospital; Shenzhen Eye Hospital

New trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion • CXCL8

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections (clinicaltrials.gov) - P=N/A | N=200 | Recruiting | Sponsor: Rigshospitalet, Denmark | Trial completion date: Sep 2025 ➔ Jan 2026 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date

Are dexamethasone implants a safe and effective breakthrough in uveitis treatment? A systematic review and meta-analysis. (PubMed, Steroids) - "Dexamethasone implants offer clinically significant benefits, resulting in substantial reductions in central retinal thickness, improvements in visual acuity, and effective control of inflammation in patients with uveitis."

Journal • Retrospective data • Cataract • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

Time-in-Range Analysis of Responses after Intravitreal Dexamethasone Therapy in Eyes with Diabetic Macular Edema. (PubMed, Ophthalmol Sci) - P3 | "The MEAD trial comprised two 3-year randomized, multicenter, sham-controlled, phase III clinical studies that evaluated the efficacy and safety of dexamethasone intravitreal implant (DEX-I) in patients with diabetic macular edema...These results suggest that patients treated with dexamethasone experience a longer time with clinically meaningful outcomes than with sham, such as being able to drive or regaining normal structural retinal features. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article."

Journal • Diabetes • Diabetic Macular Edema • Diabetic Retinopathy • Metabolic Disorders • Ophthalmology • Retinal Disorders

Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study. (PubMed, BMC Ophthalmol) - P3 | "Treatment with DEX shortened the time to DME resolution compared with sham. Higher CRT was associated with longer time to DME resolution. These findings may influence therapeutic decisions."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Macular Edema • Ophthalmology • Retinal Disorders

Impact of the Dexamethasone Implant on Slowing Diabetic Retinopathy Progression: Post Hoc Analysis of the MEAD Study. (PubMed, Retina) - "This post hoc analysis of MEAD study data showed that DEX treatment may potentially have a positive impact on DR by reducing disease severity and slowing progression in DR patients with central DME."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders